Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study

(2014) G. Curigliano et al.   JOURNAL OF CHEMOTHERAPY

Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

(2013) Lesley K. Seymour et al.   EUROPEAN JOURNAL OF CANCER

Dose-Finding Trial Designs for Combination Therapies in Oncology

(2013) Sumithra J. Mandrekar   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Adaptive designs for dual-agent phase I dose-escalation studies

(2013) Jennifer A. Harrington et al.   Nature Reviews Clinical Oncology

Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials

(2013) Adélaïde Doussau et al.   STATISTICS IN MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

(2012) Christophe Le Tourneau et al.   PLoS One

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Dose-escalation models for combination phase I trials in oncology

(2010) Paul Hamberg et al.   EUROPEAN JOURNAL OF CANCER

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges

(2010) Sumithra J. Mandrekar et al.   STATISTICS IN MEDICINE

From Theoretical Synergy to Clinical Supra-Additive Toxicity

(2009) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group

(2009) Aristotelis Bamias et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents

(2008) Guosheng Yin et al.   BIOMETRICS

Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies

(2008) Stephen A. Cannistra   JOURNAL OF CLINICAL ONCOLOGY

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

(2007) Christopher M. Booth et al.   EUROPEAN JOURNAL OF CANCER